QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.106.027425v1 70/6/1892    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rosenkilde, M. M. Articles by Schwartz, T. W. Search for Related Content PubMed PubMed Citation Articles by Rosenkilde, M. M. Articles by Schwartz, T. W.

Conformational Constraining of Inactive and Active States of a Seven Transmembrane Receptor by Metal Ion Site Engineering in the Extracellular End of Transmembrane Segment V

Laboratory for Molecular Pharmacology, Department of Pharmacology, the Panum Institute; University of Copenhagen, Denmark (M.M.R., I.O., T.B-J., T.W.S); and Institute of Biochemistry, Faculty of Biosciences, Pharmacy and Psychology, University of Leipzig, Leipzig, Germany (R.D., U.G., A.G.B-S).

The extracellular part of transmembrane segment V (TM-V) is expected to be involved in the activation process of 7TM receptors, but its role is far from clear. Here, we study the highly constitutively active CXC-chemokine receptor encoded by human herpesvirus 8 (ORF74-HHV8), in which a metal ion site was introduced at the extracellular end of TM-V by substitution of two arginines at positions V:01 and V:05 with histidines [R208H; R212H]. The metal ion site conferred high-potency inverse agonist properties (EC₅₀, 1.7 µM) to Zn(II) in addition to agonist and allosteric enhancing properties at concentrations >10 µM. The chemokine interaction with [R208H;R212H]-ORF74 was altered compared with wild-type ORF74-HHV8 with decreased agonist (CXCL1/GRO) potency (84-fold), affinity (5.8- and 136-fold in competition against agonist and inverse agonist, respectively), and binding capacity (B_max; 25-fold). Zn(II) in activating concentrations (100 µM) acted as an allosteric enhancer as it increased the B_max (7.1-fold), the potency (9.9-fold), the affinity (1.7- and 6.1-fold in competition against agonist and inverse agonist, respectively), and the efficacy (2.5-fold) of CXCL1/GRO. The activating properties of Zn(II) were not due to a metal ion site between the ligand and the receptor because CXCL1/GRO analogs in which the putative metal-ion binding residues had been substituted—[H19A] and [H34A]—acted like wild-type CXCL1/GRO. Based on the complex action of Zn(II) and on the chemokine interaction for [R208H;R212H]-ORF74, we conclude that the extracellular end of TM-V is important for the activation of this CXC-chemokine receptor.

Address correspondence to: Mette M. Rosenkilde, Laboratory for Molecular Pharmacology, Department of Pharmacology, The Panum Institute 18.6, Bleg-damsvej 3, 2200 Copenhagen N, Denmark. E-mail: rosenkilde{at}molpharm.dk.

This article has been cited by other articles:

				P. C. Jensen, R. Nygaard, S. Thiele, A. Elder, G. Zhu, R. Kolbeck, S. Ghosh, T. W. Schwartz, and M. M. Rosenkilde Molecular Interaction of a Potent Nonpeptide Agonist with the Chemokine Receptor CCR8 Mol. Pharmacol., August 1, 2007; 72(2): 327 - 340. [Abstract] [Full Text] [PDF]